Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 7/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30277756 | 1.00 | CASP1 (1.00) | CASP1ROCK2ROCK1TSHRTAAR1 | |
| SCHEMBL30277741 | 0.86 | CASP1 (0.75) | CASP1ROCK2ROCK1TSHRTAAR1 | |
| SCHEMBL5899679 | 0.84 | CASP1 (0.72) | CASP1TSHREPHX2LMNAMAPK1 | |
| SCHEMBL4856266 | 0.81 | CASP1 (0.69) | CASP1ROCK2ROCK1TSHRTAAR1 | |
| SCHEMBL7219067 | 0.78 | CASP1 (0.64) | CASP1TSHREPHX2LMNAMAPK1 | |
| SCHEMBL4852979 | 0.72 | CASP1 (0.57) | CASP1TSHREPHX2LMNAGSK3B | |
| SCHEMBL31683857 | 0.72 | CASP1 (0.57) | CASP1LMNA | |
| SCHEMBL28646625 | 0.72 | CASP1 (0.57) | CASP1LMNA | |
| SCHEMBL4851138 | 0.72 | GSK3B (0.58) | CASP1ROCK2ROCK1TAAR1GSK3B | |
| SCHEMBL5899672 | 0.72 | CASP1 (0.74) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110725-A1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-10 | — | — | US | claimed |
| US-6624166-B1 | Pharmaceutical compositions containing the compounds; and a method for inhibiting interleukin-1 beta protease activity in a mammal utilizing the compounds and compositions for enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-23 | — | — | US | claimed |
| US-6121266-A | TREATMENT/PROPHYLAXIS OF INFLAMMATORY DISEASES, IMMUNE DISEASES, CANCER | VERTEX PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | claimed |
| EP-0628550-B1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | SANOFI SA (FR) | 1998-02-25 | — | — | EP | claimed |
| EP-0628550-A2 | Pyridazines as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-14 | — | — | EP | claimed |
| US-6995261-B2 | 4-pyridazinecarboxamides and esters as interleukin-1β converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-02-07 | — | — | US | disclosed |
| US-20040110725-A1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-10 | — | — | US | disclosed |
| US-6624166-B1 | Pharmaceutical compositions containing the compounds; and a method for inhibiting interleukin-1 beta protease activity in a mammal utilizing the compounds and compositions for enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-23 | — | — | US | disclosed |
| US-6121266-A | TREATMENT/PROPHYLAXIS OF INFLAMMATORY DISEASES, IMMUNE DISEASES, CANCER | VERTEX PHARMACEUTICALS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0628550-B1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | SANOFI SA (FR) | 1998-02-25 | — | — | EP | disclosed |
| EP-0628550-A2 | Pyridazines as interleukin-1beta converting enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110725-A1 | Pyridazines as interleukin-1beta converting enzyme inhibitors | IL6ST, IL1RN, IL1R1 | CASP1 117/4885ROCK2 4268/4885ROCK1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.